The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling

Genes Chromosomes and Cancer

Volumn 52, Issue 3, 2013, Pages 225-236

  Zheng, Xin ^a,b   Gai, Xiaohong ^a,b   Han, Shaoshan ^a,b   Moser, Catherine D ^b   Hu, Chunling ^b   Shire, Abdirashid M ^b   Floyd, Robert A ^c,d   Roberts, Lewis R ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DISULFONYLPHENYL TERT BUTYLNITRONE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; ESTERASE INHIBITOR; OKN 007; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SONIC HEDGEHOG PROTEIN; SULFATASE; SULFATASE 2; TRANSCRIPTION FACTOR GLI1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEDGEHOG PROTEINS; HUMANS; IMINES; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOGENE PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SULFOTRANSFERASES; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84872398940     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22022     Document Type: Article

References (35)

1. Amaro S, Chamorro A. 2011. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 42: 1495-1499.
2. Bret C, Moreaux J, Schved JF, Hose D, Klein B. 2011. SULFs in human neoplasia: Implication as progression and prognosis factors. J Transl Med 9: 72.
3. Cheng YF, Jiang J, Hu P, Reinholdsson I, Guo W, Asenblad N, Nilsson D. 2008. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: A phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. Clin Ther 30: 2342-2353.
4. Cucchiara B, Kasner SE, Tanne D, Levine SR, Demchuk A, Messe SR, Sansing L, Lees KR, Lyden P. 2009. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: Pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke 40: 3067-3072.
5. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, Rodichok L. 2008. NXY-059 for the treatment of acute stroke: Pooled analysis of the SAINT I and II Trials. Stroke 39: 1751-1758.
6. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
7. Faivre S, Bouattour M, Raymond E. 2011. Novel molecular therapies in hepatocellular carcinoma. Liver Int 31: 151-160.
8. Floyd RA, Kopke RD, Choi CH, Foster SB, Doblas S, Towner RA. 2008. Nitrones as therapeutics. Free Radic Biol Med 45: 1361-1374.
9. Floyd RA, Chandru HK, He T, Towner R. 2011. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem 11: 373-379.
10. Garteiser P, Doblas S, Watanabe Y, Saunders D, Hoyle J, Lerner M, He T, Floyd RA, Towner RA. 2010. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Reson Imaging 31: 796-806.
11. He T, Doblas S, Saunders D, Casteel R, Lerner M, Ritchey JW, Snider T, Floyd RA, Towner RA. 2011. Effects of PBN and OKN007 in rodent glioma models assessed by 1H MR spectroscopy. Free Radic Biol Med 51: 490-502.
12. Ji W, Yang J, Wang D, Cao L, Tan W, Qian H, Sun B, Qian Q, Yin Z, Wu M, Su C. 2011. hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS One 6: e23274.
13. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR. 2008. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47: 1211-1222.
14. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. 2010a. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology 52: 1680-1689.
15. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. 2010b. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 30: 1522-1528.
16. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. 2010. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 29: 635-646.
17. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. 2002. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277: 49175-49185.
18. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. 2005. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7: 1001-1010.
19. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. 2007. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 2: e392.
20. Papoulas M, Theocharis S. 2009. Primary liver tumors: Origin and target therapy. Expert Opin Ther Targets 13: 957-965.
21. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
22. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. 1998. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273: 22936-22942.
23. Pye DA, Vives RR, Hyde P, Gallagher JT. 2000. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: Differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 10: 1183-1192.
24. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, Weitz J. 2011. Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 253: 453-469.
25. Rosen SD, Lemjabbar-Alaoui H. 2010. Sulf-2: An extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets 14: 935-949.
26. Roxburgh P, Evans TR. 2008. Systemic therapy of hepatocellular carcinoma: Are we making progress? Adv Ther 25: 1089-1104.
27. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. 2005. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem 96: 897-905.
28. Sandhu DS, Tharayil VS, Lai JP, Roberts LR. 2008. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2: 81-92.
29. Schelwies M, Brinson D, Otsuki S, Hong YH, Lotz MK, Wong CH, Hanson SR. 2010. Glucosamine-6-sulfamate analogues of heparan sulfate as inhibitors of endosulfatases. Chembiochem 11: 2393-2397.
30. Selleck SB. 2006. Signaling from across the way: Transactivation of VEGF receptors by HSPGs. Mol Cell 22: 431-432.
31. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. 2007. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562-571.
32. Thomas M. 2009. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 44: 136-141.
33. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD. 2006. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: Effects on VEGF, FGF-1, and SDF-1. Biomed Chromatogr Biochem 7: 2.
34. Whittaker S, Marais R, Zhu AX. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
35. Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, Lee JS, Thorgeirsson SS, Kang KJ, Chu IS, Roberts LR. 2011. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer 50: 122-135.